Oncology Vol 31 No 5

The Uncertainties of Rituximab and Related Therapies, 20 Years After Approval

May 15, 2017

Given the benefit of rituximab to patients, it will be important that the use of biosimilar compounds not compromise the efficacy of treatment. However, measures to improve access to anti-CD20 therapy in a cost-effective manner will clearly provide benefit to patients with lymphoma.